$7.08
3.80%
NYSE, Apr 21, 09:15 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock price

$7.36
-1.26 14.62% 1M
-1.10 13.00% 6M
-0.56 7.07% YTD
+1.90 34.80% 1Y
+3.24 78.64% 3Y
+3.97 117.11% 5Y
-7.65 50.97% 10Y
NYSE, Closing price Thu, Apr 17 2025
+0.18 2.51%
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Key metrics

Market capitalization $2.31b
Enterprise Value $4.85b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 20.65
EV/Sales (TTM) EV/Sales 1.73
P/S ratio (TTM) P/S ratio 0.83
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 16.73%
Revenue (TTM) Revenue $2.79b
EBIT (operating result TTM) EBIT $353.29m
Free Cash Flow (TTM) Free Cash Flow $234.69m
Cash position $118.42m
EPS (TTM) EPS $-0.38
P/E forward 81.78
P/S forward 0.76
EV/Sales forward 1.60
Short interest 2.20%
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
100%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,794 2,794
17% 17%
100%
- Direct Costs 1,774 1,774
15% 15%
63%
1,020 1,020
19% 19%
37%
- Selling and Administrative Expenses 240 240
20% 20%
9%
- Research and Development Expense 191 191
16% 16%
7%
589 589
20% 20%
21%
- Depreciation and Amortization 236 236
3% 3%
8%
EBIT (Operating Income) EBIT 353 353
34% 34%
13%
Net Profit -117 -117
39% 39%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
Business Wire
10 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.
Neutral
Business Wire
13 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report First Quarter 2025 Results on May 2, 2025.
Neutral
Business Wire
14 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website www.amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today